OMIDRIA Special Ep. 2 Using OMIDRIA for Mitigating Risk in Cataract Surgery

Bios:

Dr Arjan Hura (host)

Dr Arjan Hura is a cataract, refractive, and anterior segment surgeon at the Maloney-Shamie Vision Institute in Los Angeles, CA. Dr Hura is committed to the American Academy of Ophthalmology‘s mission of protecting sight and empowering lives. His research and clinical interests include working with the latest cutting-edge technology to constantly try to improve patient outcomes.

Dr Cathleen McCabe (guest)

Dr Cathleen McCabe is a cataract and refractive specialist serving as Chief Medical Officer at Eye Health America™. She is one of the foremost eye surgeons today, specializing in bladeless laser cataract surgery and LASIK at The Eye Associates in Sarasota, Florida.  Dr McCabe was recently honored for being on the Global Top 100 Power list for 2021 and 2022.

Dr Neda Shamie (guest)

Dr Neda Shamie is a cataract, LASIK and corneal surgeon and partner of the Maloney-Shamie Vision Institute in Los Angeles. She previously was the Medical Director of the Doheny Eye Institute in Beverly Hills and is an Adjunct Clinical Professor of Ophthalmology at the USC Keck School of Medicine.

 

Summary:

In this second episode of ‘Peer2Peer: The Podcast’ focused on OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%, host Dr Arjan Hura, discusses the use of OMIDRIA with Dr Cathleen McCabe and Dr Neda Shamie. They highlight the challenges faced by surgeons who suffer from high workloads and how OMIDRIA can help mitigate some of the risks associated with stress in case of complications. Additionally, they explain the benefits of using OMIDRIA with high-risk patients, and the reasons why they often apply it in less complicated cases as well.

 

Key Takeaways:

  • OMIDRIA reduces the risk of surgeries regardless of experience: Dr Shamie, Dr McCabe, and Dr Hura are all highly experienced cataract surgeons and view such surgeries as routine. Nonetheless, their experiences have shown that using OMIDRIA reduces the difficulty of surgical procedures, which is a significant boon when operating several times a day, working under pressure, or performing surgeries that require the usage of additional tools that may multiply risk and can lead to additional inflammation for the patient.
  • OMIDRIA’s positive impact is clinically proven: Dr McCabe explains that OMIDRIA’s studies have demonstrated significant CME reduction, with lower rates of rebound iritis, postoperative inflammation, and pain for the patients. This in turn requires far less deployment of risky opioid painkillers such as fentanyl.
  • OMIDRIA’s impact is heightened with high-risk patients: Shamie points out that diabetic patients, and others who are prone to inflammation, CME, miotic pupils or floppy irises may have strong benefits from OMIDRIA, as the advantages provided by what Dr McCabe refers to as incremental improvements are higher.
  • Surgeons find it easy to work with the company: Shamie explains that if there are questions regarding insurance or reimbursements, Rayner’s representatives are responsive and happy to provide support.

OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.

 

IMPORTANT SAFETY INFORMATION 

OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

 

Additional Resources:

Peer2Peer educational platform:
https://rayner.com/peer2peer-omidria/
OMIDRIA HCP Portal:
https://www.omidriahcp.com/

 

US-OM-2300031 07/23

INDICATIONS AND USAGE

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

IMPORTANT SAFETY INFORMATION

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure to phenylephrine may cause elevations in blood pressure.

Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.

The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

This site is intended for US Physician educational purposes only, using scientific exchange around the OMIDRIA experience.

Rayner, the Rayner logo, OMIDRIA, the OMIDRIA logo, and OMIDRIAssure are proprietary marks of Rayner. ©2023 Rayner Group, all rights reserved. US-OM-2200071v4 11/23